Histocell, S.L. Report issue

For profit Phase 2
Founded: Derio Bizkaia Spain (2011)

Organization Overview

First Clinical Trial
2019
NCT04289194
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Histocell, S.L.

Active Ingredients

Drugs in Phase 2 Trials (1)

HCR040 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1